1. Home
  2. BLNK vs TTRX Comparison

BLNK vs TTRX Comparison

Compare BLNK & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.70

Market Cap

99.2M

ML Signal

HOLD

TTRX

Turn Therapeutics Inc.

N/A

Current Price

$3.86

Market Cap

116.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLNK
TTRX
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
99.2M
116.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BLNK
TTRX
Price
$0.70
$3.86
Analyst Decision
Buy
Strong Buy
Analyst Count
7
1
Target Price
$2.13
$8.00
AVG Volume (30 Days)
3.4M
41.7K
Earning Date
03-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,631,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$2.57
52 Week High
$2.65
$26.50

Technical Indicators

Market Signals
Indicator
BLNK
TTRX
Relative Strength Index (RSI) 39.95 41.50
Support Level $0.64 $3.55
Resistance Level $0.72 $5.02
Average True Range (ATR) 0.06 0.33
MACD -0.01 -0.13
Stochastic Oscillator 21.10 18.36

Price Performance

Historical Comparison
BLNK
TTRX

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.

Share on Social Networks: